Vascular liver diseases

被引：12

作者：

Laurie D. DeLeve

机构：

[1] Div. of Gastrointestinal/Liver Dis., University of Southern California, Keck School of Medicine, Los Angeles, CA 90033

来源：

Current Gastroenterology Reports | 2003年 / 5卷 / 1期

关键词：

Inferior Vena Cava; Transjugular Intrahepatic Portosystemic Shunt; Portal Vein Thrombosis; Polycythemia Vera; Essential Thrombocythemia;

D O I：

10.1007/s11894-003-0011-0

中图分类号：

学科分类号：

摘要：

This article reviews the primary circulatory liver diseases, which include Budd-Chiari syndrome, obstruction of the hepatic portion of the inferior vena cava, portal vein thrombosis, sinusoidal obstruction syndrome (veno-occlusive disease), nodular regenerative hyperplasia, and peliosis hepatis. In addition, two systemic cardiovascular diseases that impair hepatic circulation, ischemic hepatitis and congestive hepatopathy, are briefly discussed. A characteristic of the primary circulatory liver diseases is that portal hypertension usually precedes liver dysfunction; however, this is not the case with the primary parenchymal liver diseases, in which liver dysfunction always progresses before portal hypertension is manifested. Significant overlap exists among the diseases and risk factors that predispose patients to the primary circulatory liver diseases, though the pathogenesis of individual diseases varies. Copyright © 2003 by Current Science Inc.

引用

页码：63 / 70

页数：7

共 50 条

[1]

Okuda K., Kage M., Shrestha S.M., Proposal of a new nomenclature for Budd-Chiari syndrome: Hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion, Hepatology, 28, pp. 1191-1198, (1998)

[2]

Denninger M.H., Chait Y., Casadevall N., Et al., Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors, Hepatology, 31, pp. 587-591, (2000)

[3]

Janssen H.L., Meinardi J.R., Vleggaar F.P., Et al., Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: Results of a case-control study, Blood, 96, pp. 2364-2368, (2000)

[4]

Rosenberg R.D., Aird W.C., Vascular-bed-specific hemostasis and hypercoagulable states, N. Engl. J. Med., 340, pp. 1555-1564, (1999)

[5]

Ryu R.K., Durham J.D., Krysl J., Et al., Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome, J. Vasc. Interv. Radiol., 10, pp. 799-805, (1999)

[6]

Ganger D.R., Klapman J.B., McDonald V., Et al., Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis, Am. J. Gastroenterol., 94, pp. 603-608, (1999)

[7]

Campbell Jr. D.A., Rolles K., Jamieson N., Et al., Hepatic transplantation with perioperative and long term anticoagulation as treatment for Budd-Chiari syndrome, Surg. Gynecol. Obstet., 166, pp. 511-518, (1988)

[8]

Slakey D.P., Klein A.S., Venbrux A.C., Et al., Budd-Chiari syndrome: Current management options, Ann. Surg., 233, pp. 522-527, (2001)

[9]

Tefferi A., Solberg L.A., Silverstein M.N., A clinical update in polycythemia vera and essential thrombocythemia, Am. J. Med., 109, pp. 141-149, (2000)

[10]

Cortelazzo S., Finazzi G., Ruggeri M., Et al., Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis, N. Engl. J. Med., 332, pp. 1132-1136, (1995)

← 1 2 3 4 5 →